Guide — Renal
Kidney Transplant Nursing Guide
Pre-transplant evaluation, surgical placement, rejection types (hyperacute/acute/chronic), immunosuppression medications, post-transplant nursing priorities, infection risk management, and patient education for kidney transplant nursing.
12 min read · Renal
Educational use only. Transplant nursing is a specialized field. Clinical protocols vary by institution and transplant program. Always follow center-specific guidelines. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Transplant Basics
| Surgical placement | Heterotopic (iliac fossa — right > left). Native kidneys usually left in place (unless causing hypertension or recurrent UTIs). Donor ureter anastomosed to recipient bladder. |
| Donor types | Living donor (related or unrelated — better outcomes) vs Deceased donor (brain-dead donor or donation after circulatory death/DCD — more common). |
| HLA matching | Human leukocyte antigen (HLA) compatibility reduces rejection risk. Perfect 6/6 antigen match = best; 0/6 = highest rejection risk. Crossmatch testing detects preformed antibodies. |
| Delayed graft function (DGF) | Kidney does not function immediately post-transplant (requires dialysis in first week). More common with deceased donor kidneys. Usually resolves — not rejection. Monitor closely; do NOT assume rejection without biopsy. |
| Pre-transplant evaluation | PRA (panel-reactive antibody level), ABO blood type compatibility, cardiac evaluation, cancer screening, infection screening (HIV, hepatitis B/C, CMV, EBV — all affect post-transplant management), psychosocial evaluation, medication adherence assessment. |
Rejection Types
Hyperacute Rejection
Timing: Minutes to hours after reperfusion · Reversibility: NO — irreversible
| Mechanism | Preformed recipient antibodies (anti-HLA) bind to donor endothelium → complement activation → thrombosis → immediate graft necrosis |
| Presentation | Immediate loss of graft function during surgery; kidney turns dusky/blue-black; no urine output |
| Treatment | No treatment possible — graft must be removed (transplant nephrectomy) |
| Nursing Action | Recognize post-operative anuric patient in OR who has no urine output — immediate notification to surgeon. Post-transplant: prepare patient for graft loss discussion. |
Acute Rejection
Timing: Days to weeks (typically within 3–12 months; can occur anytime) · Reversibility: OFTEN REVERSIBLE with early detection and treatment
| Mechanism | T-cell mediated (cellular rejection) or antibody-mediated (humoral). T cells recognize donor HLA antigens → cytokine release → inflammatory infiltration → tubular injury |
| Presentation | Rising creatinine, decreased urine output, graft tenderness, fever, hypertension. Often asymptomatic early — detected on routine creatinine monitoring. |
| Treatment | Pulse corticosteroids (IV methylprednisolone 500 mg–1g × 3 days). Antibody-mediated: plasmapheresis + IVIG + rituximab. |
| Nursing Action | Daily creatinine monitoring. Immediately report any creatinine rise above baseline. Teach patient: any fever, decreased UO, or graft tenderness = call provider IMMEDIATELY. Adherence to immunosuppression is critical. |
Chronic Rejection / Chronic Allograft Nephropathy
Timing: Months to years (typically > 1 year post-transplant) · Reversibility: NO — irreversible (most common cause of late graft loss)
| Mechanism | Complex combination of immune-mediated (antibody-mediated, T-cell) and non-immune factors (hypertension, calcineurin inhibitor nephrotoxicity, ischemia, diabetes). Progressive fibrosis and intimal hyperplasia. |
| Presentation | Gradual creatinine rise, proteinuria, hypertension. Ultimately graft failure requiring return to dialysis or retransplantation. |
| Treatment | No treatment reverses it. Manage risk factors. Optimize immunosuppression. Prepare for return to dialysis or retransplant listing. |
| Nursing Action | Long-term monitoring: creatinine trends, proteinuria, BP control. Educate on lifestyle modifications. Emotional support — chronic rejection is the leading cause of long-term graft loss. |
Immunosuppression Medications
Tacrolimus (FK506, Prograf)
Calcineurin inhibitor — primary maintenance immunosuppressant
| Mechanism | Inhibits calcineurin → blocks IL-2 production → T-cell inactivation |
| Monitoring | Trough level (before morning dose). Target varies: 8–12 ng/mL (early), 5–8 ng/mL (late). Creatinine, glucose, BP, lipids. |
| Side Effects | Nephrotoxicity, hypertension, hyperglycemia (post-transplant diabetes mellitus), hyperkalemia, neurotoxicity (tremors, headache, insomnia), hypomagnesemia, drug interactions |
| Nursing Notes | Same time daily (every 12 hours). NEVER skip doses. Trough level drawn before morning dose. Report tremors, HA, rising glucose, or creatinine. Do NOT take with grapefruit juice (inhibits CYP3A4 → supratherapeutic levels). |
Mycophenolate Mofetil (MMF, CellCept) / Mycophenolic acid (MPA)
Antiproliferative — anti-metabolite
| Mechanism | Inhibits inosine monophosphate dehydrogenase (IMPDH) → blocks purine synthesis → inhibits T and B cell proliferation |
| Monitoring | CBC (neutropenia risk), GI tolerance. MPA levels at some centers. |
| Side Effects | GI toxicity (N/V/D, abdominal cramps), leukopenia (neutropenia), anemia, infection risk, teratogenic |
| Nursing Notes | Give with food to reduce GI side effects. Enteric-coated formulation (Myfortic) also available. Report any signs of infection. TERATOGENIC — counsel women of childbearing age on contraception. Handle capsules with care (wash hands, no crushing). |
Prednisone / Methylprednisolone
Corticosteroid — anti-inflammatory and immunosuppressive
| Mechanism | Inhibits cytokine production (IL-1, IL-2, IL-6, TNF), blocks phospholipase A2, reduces inflammation |
| Monitoring | Blood glucose (steroid-induced hyperglycemia), BP, weight, bone density (long-term), eye exam (cataracts), mood. |
| Side Effects | Cushing features (moon face, buffalo hump), hyperglycemia, HTN, osteoporosis, cataracts, adrenal suppression, impaired wound healing, infection risk, mood changes |
| Nursing Notes | Never abruptly stop — taper to avoid adrenal crisis. Take with food to reduce GI irritation. Monitor blood glucose closely, especially in first weeks post-transplant. Teach patient: infection signs are masked by steroids. Bone protection: calcium, vitamin D, bisphosphonates. |
Basiliximab (Simulect)
IL-2 receptor antagonist — induction agent
| Mechanism | Monoclonal antibody — blocks IL-2 receptor on activated T cells → prevents T-cell proliferation during high-risk early period |
| Monitoring | No therapeutic drug monitoring. Monitor for hypersensitivity reactions. |
| Side Effects | Well tolerated. Rare: anaphylaxis, hypersensitivity. Does not increase overall infection risk significantly. |
| Nursing Notes | Administered as IV infusion. Monitor for infusion reactions. Used as induction to provide additional immunosuppression during the first weeks when rejection risk is highest. |
Post-Transplant Nursing Priorities
| Priority | Nursing Action |
|---|---|
| Urine output monitoring | Hourly UO in immediate post-op. Goal > 30 mL/hr (often much higher in first 24–48h). Sudden decrease = call provider immediately (rejection, obstruction, thrombosis, or volume depletion). |
| Creatinine trend | Daily creatinine in early post-transplant. Rising creatinine = rejection vs drug toxicity vs obstruction — requires evaluation and often biopsy. Do NOT assume one cause without workup. |
| Blood pressure | Target < 130/80 mmHg. Hypertension common post-transplant (tacrolimus, cyclosporine, steroid effects). Anti-hypertensives as ordered. Avoid hypotension (reduces graft perfusion). |
| Infection prevention | Highest infection risk in first 6 months (highest immunosuppression). Universal precautions, strict hand hygiene, no fresh flowers or standing water in room (Aspergillus), food safety (no raw/undercooked food). Prophylactic medications: TMP-SMX (PCP prophylaxis), valganciclovir (CMV prophylaxis if indicated), antifungals. |
| Blood glucose | Post-transplant diabetes mellitus (PTDM) occurs in ~15–30% (steroids + tacrolimus). Monitor blood glucose QID initially. Sliding scale insulin or standing insulin as ordered. |
| Wound care | Steroids impair wound healing. Assess surgical site for dehiscence, hematoma, lymphocele. Foley catheter care (usually removed at day 5–7 once anastomosis healed). Report any drainage or fever. |
| Medication compliance | NEVER skip immunosuppression. Even one missed dose can trigger rejection. Medication reconciliation at every contact. Teach: always refill before running out. Avoid grapefruit with tacrolimus/cyclosporine. |
Patient Education Priorities
- Medications: Never stop immunosuppression without provider guidance — this causes rejection. Take at exactly the same time each day.
- Signs of rejection to report immediately: decreased urine output, weight gain, swelling, fever, graft tenderness, rising creatinine (on home monitoring).
- Infection signs to report: fever > 38°C (100.4°F), dysuria, respiratory symptoms, wound redness/drainage.
- Sun protection: Immunosuppression dramatically increases skin cancer risk — daily sunscreen SPF 50+, protective clothing, annual dermatology screening.
- Diet and food safety: Avoid raw or undercooked meat/fish (Listeria, Salmonella risk). Wash produce. Avoid grapefruit and grapefruit juice.
- Follow-up: Frequent laboratory monitoring (initially weekly, then monthly, then quarterly). Never miss appointments — silent rejection is detected only on labs.
- Vaccinations: No live vaccines post-transplant. Inactivated vaccines recommended (influenza annually, pneumococcal). Verify all vaccines before transplant while still immunocompetent.
NCLEX Pearls
Hyperacute rejection: minutes to hours, preformed antibodies, irreversible — graft removed. Prevented by crossmatch.
Acute rejection: days to weeks, T-cell mediated, often reversible with pulse steroids. Report rising creatinine immediately.
Chronic rejection: months to years, most common cause of long-term graft loss, irreversible.
Tacrolimus trough drawn BEFORE morning dose. No grapefruit — inhibits CYP3A4 → toxic levels.
No live vaccines post-transplant (MMR, varicella, live attenuated influenza, yellow fever).
Kidney is placed in iliac fossa (heterotopic) — NOT in the original kidney location.
Immunosuppression = infection risk. Low-grade fever in transplant recipient = emergency — may not have normal inflammatory response.
Delayed graft function ≠ rejection — DGF requires dialysis post-op but usually resolves. Biopsy differentiates DGF from rejection.
Related Resources
Standards & sources
Fact-checked Jun 21, 2026This page is written to align with KDIGO Clinical Practice Guidelines · National Kidney Foundation (NKF). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →